Mycobacterium leprae
1.
Introduction Leprosy, a debilitating disease of the skin and peripheral nerves, continues to remain as a constant peril with approximately 135,752 cases from India alone in 2013 [1] . Mycobacterium leprae, the causative organism for this disease, has a long incubation period of 3-7 years during which the bacteria remain dormant or multiply in the Schwann cells of the neuronal myelin and manifest a spectrum of clinical outcomes [2] . These outcomes can range from a self-limiting, cellmediated immunity predominant tuberculoid pole (TT) with minimal bacillary load in the skin and nerves to a more systemic, humoral-immunity predominant lepromatous pole with high bacillary load. These polar forms are interspersed by three intermediary unstable borderline forms (borderline tuberculoid [BT] , midborderline, and borderline lepromatous) in which the diagnosis of the disease is often based on clinical manifestations and histopathological features [3] . These clinical signs are very minimal and often confounding in the TT and BT forms and hence pose diagnostic challenges. World Health Organization (WHO) has introduced a more convenient field based classification called the multibacillary (MB) leprosy with greater than five skin lesions and paucibacillary (PB) leprosy with less than five skin lesions [4] .
During the incubation phase between the infection and manifestation of clinical symptoms, the disease may remain subclinical and chronically progress to a systemic phase which predisposes nerve damage and subsequent deformities [5] . Therefore, it is important to diagnose the disease early in a subclinical state in order to treat it rapidly and prevent deformities. In this context, an early diagnostic test has long been desired for leprosy [6] . To date, there is no specific screening test and/or assay that aids in early diagnosis of leprosy with substantial sensitivity and specificity [7] . While the bacteriological index (BI) determination in the slit skin smears and histopathological examination of the skin biopsy sections remained as clinical and pathological methods for determination of bacillary load, the sensitivity of these tests is limited to the few microscopic sections being examined. Detection of M. leprae gene targets (RLEP, 16SrRNA, SodA, Ag85A, PRA, etc.) in the DNA extracted from the skin biopsies and peripheral blood samples of leprosy patients comparatively presented higher sensitivity especially in the indeterminate, TT, and BT forms where the BI remains negative due to low bacterial counts [8, 9] . However, some of these gene targets have questionable specificity.
To date, the known gene target that remains specific to M. leprae genome is the RLEP gene [10] , which is a repetitive element in the genome of M. leprae [11] . Real-time polymerase chain reaction (PCR) based detection using RLEP PCR assays could detect 70% of PB leprosy in which the BI is negative [12] . However, simple conventional nested PCR assay with a 129-bp fragment could detect only 55.5% of the BI negative PB cases [13] . While it was reported that RLEP real-time PCR assay can detect M. leprae DNA in as little as 8 fg (indicating 3 bacterial cells per sample, taking a 3.2-mbp genome into calculation), the 129-bp fragment missed on identifying 30-50% of the BI negative PB cases when used in a conventional PCR [14] . Hence there is a need for identification of specific and sensitive M. leprae gene targets that aid in diagnosis of leprosy cases with negative BI or very minimal bacillary load using simple conventional PCR.
In this study, we examined M. leprae specific and unique DNA sequences in pseudogenes and identified a 112-bp sequence in the promoter region of ML1545 (probable 4-alpha-glucanotransferase [pseudogene]) which possess substantial specificity. Further, we investigated the utility of this gene sequence as a target for PCR-based detection of M. leprae DNA in the clinical isolates of leprosy patients. The PCR positivity was compared to that of RLEP to determine the sensitivity in detection of M. leprae DNA in leprosy cases across the spectrum of the disease.
2.
Materials and methods (Table 1 ). In addition, six healthy individuals who reside in a low endemic area and without any direct contacts with active leprosy cases, were enrolled as controls. DNA extracted from Mycobacterium tuberculosis, Mycobacterium smegmatis, and Mycobacterium phlei was used as a technical control to ascertain the specificity of ML1545.
Sample types
Part of the 5 mm Â 5 mm excisional skin biopsy that was collected for routine histopathological examination was used for the experiments in the current study. Ridley Jopling classification and BI were recorded at diagnosis for all the participants. The clinical characteristics of the participants were represented in Table 1 .
DNA extraction
DNA was extracted from skin biopsy specimens following the lysis protocol which was reported earlier, with minor modifications [15] . Briefly, 25 mg of tissue was thoroughly homogenized using a manual homogenizer and homogenate was added to 1 mL of 1X phosphate buffer saline and centrifuged at 8000 rpm for 10 min at 4°C. The pellet was dried for 1 h at 50°C on a dry block incubator and was later used in the lysis protocol. Two hundred microliters of lysis buffer (containing 100 mM Tris buffer at pH 8.5, 1 mg/mL proteinase K, and 0.05% Tween 20) was added to the homogenate in a 1.5-mL microcentrifuge tube, vortexed thoroughly, and incubated at 60°C for 16 h in a water bath (Cole-Parmer Polystat Inc., Chicago, IL, USA). Post incubation, proteinase K was deactivated at 95°C for 15 min. Later the lysate was allowed to cool to room temperature and DNA was eluted using phenol chloroform extraction. DNeasy Kit (Cat No: 69504; Qiagen Inc., Valencia, CA, USA) was used in some samples where the tissue content was apparently low. DNA extraction from cultures of M. tuberculosis, M. Smegmatis, and M. phlei was also performed using the same protocol.
Selection of the gene target (ML1545) and primer design
A sequential search of M. leprae specific DNA sequences in pseudogenes was performed using National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) and PatricBRC Portal (https://www.patricbrc.org). A set of eight genes that include ML1127, ML2110, ML2211, ML0203, ML0307, ML1545, ML2177, and ML0466 were identified to harbor sequences that remain specific for M. leprae genome. However, upon further analysis of these individual sequences using NCBI BLAST with various database search parameters like ''NCBI Genomes" (chromosomes) and ''Reference genomic sequences" within Mycobacteria and Mycobacteriaceae, a DNA sequence that traverses the promoter region of probable 4-alpha-glucanotransferase (ML1545) gene was chosen as it remained highly specific to the genome. Primers were designed while maintaining the specificity using Primer BLAST version 3 from NCBI. The sequence for the forward primer is 5 0 -GTCCTCCGTCTTGCTG ACTG-3 0 and for the reverse primer is 5 0 -CATACCGGCCA TATTGCGTC-3 0 . The designed primers were obtained commercially from Eurofins Scientific Inc., Germany. The PCR amplifications with these primers were compared with those of the RLEP whose primers were taken from the earlier reports [16] . conditions. The presence of DNA in the samples was confirmed through the amplification of the rpoB gene region in all three species using specific primers and PCR conditions [17] .
PCR conditions and cycling parameters

Statistical analysis
Statistical analysis of the data was performed using GraphPad Prism 6 software (GraphPad Software, Inc. CA, USA). Z test of proportions was used to compare the PCR positivity between the two gene targets. An association with p < 0.05 is considered statistically significant.
Results
PCR and sequence determination of 112-bp fragment flanking the promoter region of ML1545
The PCR amplification of ML1545 revealed a 112-bp fragment (Fig. 1 ) whose sequence was confirmed through Sanger DNA sequencing. BLAST alignment with the known genomic repository of NCBI (Gen Bank Accession: FM211192) for M. leprae BR4923 and M. leprae TN strains revealed that the sequence spans nucleotide positions 1868137-1868248 in the BR4923 strain and 187412-187523 in the TN strain (Fig. 2) . This sequence was chosen owing to its specificity to M. leprae and the absence of this sequence in other mycobacteria.
3.2.
Comparison of PCR positivity between ML1545 and RLEP Comparative assessment of PCR positivity among the leprosy patients revealed that 164/180 (91.11%) were positive for ML1545 when compared with 114/180 (63.33%) for the RLEP (p < .0001, z = 6.3). Of the 180 samples, 108 (60.00%) samples were positive for both of the gene targets, 10 (5.56%) samples were negative for both ML1545 and RLEP, 56 (31.11%) samples were positive for ML1545 and negative for RLEP, and six (3.33%) samples were negative for ML1545 and positive for the RLEP (p < .0001, z = 7.1; Table 2 ). Of the ML1545 positive and RLEP negative samples (n = 56), 24 (42.85%) samples had a negative BI, 6 (10.71%) were cases of PB leprosy, 17 (30.35%) were cases of BT and indeterminate leprosy, and 9 (16.07%) were cases with other clinical forms of leprosy.
Comparison of PCR positivity of ML1545 and RLEP across various clinical forms in leprosy
Attribution of PCR positivity of ML1545 and RLEP to various clinical forms in leprosy as classified according to WHO regimen of MDT, RJ classification, and BI revealed that 103 (63.58%) of 162 MB leprosy cases were positive for RLEP and 150/162 (92.59%) were positive for ML1545 (p = .0001, z = 6.0). Of the 42 BT leprosy cases, 23 (54.76%) were positive for RLEP whereas 37 (88.09%) were positive for ML1545 (p = .0006, z = 3.4). In the lepromatous pole group, 52 (72.22%) out of the 72 samples were positive for RLEP whereas 69 (95.83%) were positive for ML1545 (p = .0002, z = 3.7). Importantly, among the 58 leprosy cases with negative BI, 28 (48.28%) were Fig. 1 -Two percent agarose gel electrophoresis of the ML1545 gene amplicons from a representative set of two leprosy cases (S1 and S2). Note. NC = negative control (nuclease free water); PC = positive control (DNA extracted from Mycobacterium leprae Br4923). positive for RLEP and 48 (82.76%) were positive for ML1545 (p = .0001, z = 3.8). In the BI positive groups, among 122 leprosy cases, 86 (70.49%) were positive for RLEP whereas 116 (95.08%) were positive for ML1545 (p < .0001, z = 5.1). These results indicate that ML1545 has statistically significant higher PCR positivity in various clinical forms of leprosy when compared with RLEP using conventional gradient PCR. Comparisons within other groups were not detailed due to low sample numbers in each group; however, they were represented in Table 3 . These observations provide a preliminary lead to the utility of ML1545 as a PCR target for diagnosis of leprosy, especially among leprosy cases with low bacillary load.
PCR assessments in control groups and other mycobacterial species
Our results indicated that six nonendemic healthy controls were PCR negative for RLEP or ML1545. Specificity assessments with DNA extracted from M. tuberculosis, M. smegmatis, and M. phlei revealed that all three species were negative for PCR with RLEP as well as ML1545. Presence of bacterial DNA in the samples was determined using PCR for rpoB gene region of all three species which indicated positive PCR results. These control experiments indicate that RLEP as well as ML1545 are specific for M. leprae and do not show any cross amplification with other mycobacterial species.
Discussion
Diagnosis of leprosy has always remained a challenging task for clinicians and dermatologists because the disease follows an immunological spectrum wherein TT and BT forms are often misdiagnosed due to the lack of clear and evident clinical manifestations, especially in a setting where histopathological examination is not available. PCR has proved to be a great support in diagnosis of TT and PB leprosy where the BI is negative. In the past 20 years, PCR has been definitively used in detecting M. leprae DNA in clinical specimens of various types, including slit skin scrapings, nerves, nasal swabs, oral swabs, ocular lesions, urine, and blood [18] [19] [20] [21] [22] . Various M. leprae gene targets have been chosen and analyzed for their sensitivity and specificity in a diagnostic setting. A 530-bp gene encoding a proline-rich antigen [23] was used in the detection process and later genes like Ag85B [9] , sodA, and 16SrRNA [12] have also been analyzed for their utility in diagnosis. Identification of RLEP, a repetitive sequence of M. leprae which demonstrated higher sensitivity and specificity than earlier reported gene targets, enabled detection of low levels of M. leprae DNA [24] . Donoghue et al. [10] first reported the amplification of the 129-bp fragment of the RLEP gene using nested PCR in DNA extracted from skin biopsies of leprosy cases. It has been noted that conventional RLEP PCR indicated a 30-50% positivity in leprosy cases with negative BI and around 80% in cases with acid fast bacilli in the smears [25] . The quantitative PCR with RLEP revealed 87.1% sensitivity [26] and the application of RLEP real-time PCR assays has enabled the detection of 75% of PB leprosy cases [14] . While the target remained highly specific for M. leprae, the sensitivity values in patient groups especially in TT and BT forms of the disease remained moderate. Although real-time quantitative PCR using RLEP assays proved useful, their application is limited due to costs associated with the assays. Hence, in endemic countries and in resource limited field and patient settings, a gene target that can demonstrate at least 80-90% sensitivity for M. leprae DNA using conventional gradient PCR is important for confirmatory diagnosis especially in cases with low bacillary load and where diagnosis is difficult. Additionally, the specificity of RLEP gene amplification using conventional PCR has not been adequately established. RLEP gene also has conserved sequences which raises a possibility of the presence of homologous sequences in other mycobacterial genomes [7, 14] .
We reported for the first time about the utility of ML1545 for PCR-based diagnosis of leprosy with conventional PCR. This novel target was able to determine 82% of leprosy cases with negative BI, demonstrating a higher sensitivity in cases with low bacillary load. The target remained highly specific for M. leprae as noted from the BLAST results with the amplicon sequence and also from the PCR amplifications in three other related mycobacterial species. The results indicate only a preliminary assessment of this M. leprae specific gene target in clinical samples using conventional PCR; however, there is scope for further assessments that include determination of mRNA expression levels of the target across various study groups. An assay which is similar to that of the RLEP realtime PCR assay can be developed for ML1545 to determine the sensitivity limit of this gene target in detecting M. leprae DNA extracted from various tissue sources of leprosy patients. Also, the utility of this specific target has not been investigated in contacts of leprosy cases. Further studies in this area may provide insights into the utility of ML1545 in determining subclinical infection in leprosy, owing to its higher sensitivity.
In conclusion, ML1545 can be a potential gene target for PCR-based diagnosis of leprosy especially in leprosy cases with low bacillary load and negative BI and in cases that are in the TT and BT forms. The target may prove useful in a basic diagnostic laboratory where conventional PCR machines are available.
